Cytosorbents Corp Stock Price, News & Analysis

CytoSorbents Corporation (NASDAQ: CTSO) announced a pivotal study published in Biomedicines demonstrating the early initiation of its CytoSorb technology in critically ill septic shock patients. The study showed a significant reduction in norepinephrine requirements (>50%) and lower in-hospital mortality rates (21.4% vs. 47.6%) among 42 patients treated with CytoSorb compared to matched controls. Early intervention, within 24 hours of ICU admission, was highlighted as crucial for enhancing survival outcomes. This research supports the continued evaluation of CytoSorb's effectiveness in critical care scenarios.

On December 2, 2020, CytoSorbents Corporation (NASDAQ: CTSO) announced an international fundraising campaign to raise $100,000 for CARE USA, supporting its COVID-19 Emergency Fund. The campaign runs until January 31, 2021, coinciding with the company’s milestone of having shipped over 100,000 CytoSorb cartridges globally. CytoSorbents will match donations dollar-for-dollar, reinforcing its commitment to improving lives in communities it serves worldwide. The funds will aid programs focused on sanitation and education to combat the spread of COVID-19 and other diseases.

On Nov 25, 2020, CytoSorbents Corporation (NASDAQ: CTSO) announced the publication of the largest case series using its CytoSorb blood purification technology in critically ill COVID-19 patients. This study, published in Artificial Organs, assessed 50 patients requiring renal replacement therapy. The findings revealed a 70% survival rate at 28 days post-ICU admission, with statistically significant improvements in key inflammatory markers after treatment. The CEO highlighted the relevance of the study amid ongoing COVID-19 surges, emphasizing the need for effective therapies during the pandemic.

CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy, announced its participation in the Piper Sandler 32nd Annual Healthcare Conference from November 23 to December 3, 2020. The company will hold 1x1 investor meetings from December 1-3. CytoSorbents specializes in blood purification using its flagship product, CytoSorb®, which addresses deadly inflammation in critically-ill patients and has been utilized in over 110,000 treatments globally. For more information, visit their website.

CytoSorbents Corporation (NASDAQ: CTSO) announced it will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020, showcasing its CytoSorb® blood purification technology. This technology targets deadly inflammation in critically ill patients. The presentation will occur from 2:40 PM to 3:10 PM GMT (9:40 AM to 10:10 AM EST). Investors can schedule one-on-one meetings via Jefferies. CytoSorb® has been applied in over 110,000 human treatments and received various CE-Mark label expansions.

CytoSorbents Corporation (CTSO) reported impressive Q3 2020 financial results with total revenue reaching approximately $10.5 million, a 73% increase from Q3 2019. Product revenues surged by 79% to $10.2 million. The gross margin improved sequentially to 74%, despite a slight decrease year-over-year. The company ended September with $88 million in cash, a significant increase compared to June. Operational highlights included over 110,000 CytoSorb treatments and a contract worth $4.4 million from the U.S. Department of Defense, aimed at advancing blood transfusion safety.

CytoSorbents Corporation (CTSO) will announce its Q3 2020 financial results on November 4, 2020, after market close. The company specializes in critical care immunotherapy using its CytoSorb® technology for blood purification. Management will host a conference call at 4:45 PM Eastern on the same day to discuss operational and financial progress, which will be followed by a Q&A session. CytoSorb has been used in over 100,000 human treatments and is approved in the EU and 65 countries globally.

CytoSorbents Corporation (NASDAQ: CTSO) and Aferetica have received European Union approval for their innovative PerLife™ ex vivo organ perfusion system and ECOS-300CY™ sorbent cartridge. This integrated system aims to enhance the preservation and quality of kidneys and livers prior to transplant. The commercial launch is planned for Italy this quarter. The PerLife system is designed to remove inflammatory mediators, thereby increasing the success rates of solid organ transplants amid rising global demand due to health crises like diabetes and obesity.

CytoSorbents Corporation (NASDAQ: CTSO) has been awarded a two-year SBIR Sequential Phase II contract valued at $1,098,588 by the U.S. Army Medical Research Acquisition Activity. The funding aims to optimize the development of the HemoDefend-BGA™ adsorber, capable of removing over 99% of blood group antibodies to create a 'universal plasma' for emergency treatment. This follows prior contracts totaling approximately $7.5 million to enhance their blood purification technologies, which are crucial for treating critically ill patients.